Compare HSBC Holdings plc (HSBC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Smith & Nephew plc — how do they compare? HSBC Holdings plc trades at $92.83 (market cap $311.92B), while Smith & Nephew plc trades at $27.05 (market cap $11.10B). The key difference: HSBC Holdings plc is far larger — about 28.1× Smith & Nephew plc's market cap, and HSBC Holdings plc pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Smith & Nephew plc for 120 Days on average.
| HSBC | SNN | |
|---|---|---|
Market Cap | $311.92B | $11.10B |
Volume | 3,546,658 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $107.86 | $37.17 |
52-Week Low | $65.67 | $26.42 |
Typical Hold Time | 36 Days | 120 Days |
Enterprise Value | $222.19B | $14.13B |
Dividend Yield | 4.05% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.80, down 0.97% with bearish technical signals. The stock shows strong profitability with 34.54% net margin and reasonable valuation at 13.23 P/E. Recent earnings were mixed with Q2 beat but Q1 miss. Analyst sentiment is cautious with 38% buy ratings. The bank is expanding in technology banking and US wealth services while restructuring European operations.
HSBC offers value with solid fundamentals but faces near-term headwinds from technical weakness and mixed earnings performance. Growth opportunities in Asian markets and wealth management balance risks from European restructuring and CFO transition in 2027.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
